ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy

Dr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Haven, Connecticut, review clinical research data and best practices guiding the selection of first-line and maintenance therapy for patients with ER-positive, HER2-positive metastatic breast cancer. CME information and select publications here.